Roy A. Whitfield, Director at NEKTAR THERAPEUTICS (NKTR), sold 30,000 shares at $0.57 ($17K) on 2023-06-14, disclosed to the SEC on 2023-06-15.
Scheduled sale ($17k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| ILMN | SELL | 2016-08-15 | $669K | — | Filing → |
| ILMN | SELL | 2016-06-15 | $534K | — | Filing → |
| ILMN | SELL | 2016-04-14 | $680K | — | Filing → |